The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
FT ARTICLE
https://markets.ft.com/data/announce/full?dockey=1323-14984072-3FM5Q2BOG6N9G068IEARRRMHQ7
Issuance of key TMT® Patent and Introduction of 18plex TMTpro™ Services
Proteome Sciences is pleased to announce the issuance to it of U.S. Patent No. 10,976,321 relating to methods of analysis using isobaric mass tags. This patent, which covers the TMTcalibrator™ workflow, enables enhanced fluid biomarker discovery and single-cell proteomics and forms part of the intellectual property exclusively licensed to Thermo Fisher Scientific by the Company. Commercial users interested in performing any of the methods covered by U.S. Patent No. 10,976,321 or its foreign counterparts should contact the Thermo Fisher Scientific Licensing Team.
The Company is also launching new higher-throughput services using a recently developed, extended range of TMTpro™ reagents that now provide 18 channels, increasing throughput and enabling quantification of 100 samples in only 6 experiments.
Commenting, Dr. Ian Pike, Chief Scientific Officer, said: "These are key developments for the Company as we see increasing demand for our services across the drug-development and academic sectors. U.S. 10,976,321 is a key patent covering our TMTcalibrator™ technology, which is at the heart of our precision medicine efforts. We are updating the technology access program with our exclusive licensee Thermo Fisher Scientific, offering commercial users and providers of contract research services (CROs) an efficient way to obtain licenses to the TMT® patent portfolio where required.
Combined with the extension of TMTpro™ to 18plex, this represents the most powerful proteomics platform to identify and develop biomarkers that are essential to developing personalised medicine through more efficient, large-scale blood biomarker proteomics, as well as enabling the emerging field of single-cell proteomics".
Yes lovely communication and increasing confidence and awareness generated .. excellent progress . I feel we will have a very good year !
...to buy again before a very positive RNS this evening! SP ended this awful day up a squidgeon. Hopefully further progress coming.
Thank you AngelMarbles. Can't profess to understand it all but just doubled my holding anyway. Convinced this science is at last having its day (hopefully longer than that!)
Randox webinar tomorrow about QC software if anyone interested
Throughout the webinar, key speaker Margaret Le Roux will highlight the benefits of implementing a quality control software in a laboratory, specifically focusing on the use of sigma metrics, %bias, total error, uncertainty of measurement and other statistical reports.
This discussion will be beneficial for laboratories looking to work more efficiently and effectively. An automated QC software, such as Acusera 24•7, can help to enhance performance assessment, improve QC strategy and meet regulatory requirements.
https://www.randox.com/european-acusera-247-webinar/
.... for the bid! IDH has just got one and this could be next!
Look at the Randox video which has pinpointed key targets for future health diagnostics ..
https://youtu.be/2kPOS1X5NnE
Yes it is
Interesting to see three buys totalling 950,000 shares posted yesterday. Another positive sign?
We need a comprehensive brokers note. But the CEO said in the presentation they would really have to provide most of the data and help the broker to release one. It is something they are working on/or rather thinking about
Thanks pal
Hayashi , all I can say PRM r the best at what they do :- think of the extent for UK|Europe where we have a base in Frankfurt germany . with medicine and biotechs all companies need fda approval showing proteome interplays to proceed with diseases/medicines. The US proteomics companies are significantly much in the forefront and in the news. I would expect this to go into the early teens and on .. we need more awareness and understand of our unique position in this sector
You were right about the modest correction. The other board seems to be looking back with bitterness....probably better to look forward. Have not seen any research so no idea what price targets might be appropriate for this share. I'm inclining to add some more.
Looking good, bound to be a bit of a correction though before carrying on with the re-rate. In profit now on a fair chunk of my holding, a couple more pennies and am there with 90% of it. Still have 100K in my old charles schwab/barclays account, that will be under water for some time to come i suspect. May sell it to take the loss and use the loss against cgt elsewhere
Took some yesterday arvo @ around 7.8 based on it breaking the upside of the chart, looks good for a consistent move. In to the teens next week?
Welcome to the new PRM'ers
You have saved yourself 20 years of pain and probably bought in at just the right time. Quite amazing that they have stayed afloat for so long but now its self funding it finds itself in an area with a very bright future. I think some m&a activity could be on the cards soon which could see PRM on the acquisition trail unless we are the target. That could temporarily hit the share price as we go for growth. but then makes us an even juicier target ourselves.
Having averaged right down over the last two years, I had planned to sell if i ever broke even, not planning to do that anymore.
Do you have a price target in mind Angel? I came across this share a few weeks ago and bought some..glad I did now.
Have been trying to understand the proposition. New ceo lady seems impressive.
Yes, the FT had one of these purchases in its saturday paper a few weeks ago and caught my attention. After a little research I thought it was worth a punt.
What a lovely day !
I think stay a while longer ! We are so undervalued abdca sector that is so vital , so inherent to diagnostics /medical development , also lovely to see new posters here as I’ve been prm advocate for a while .. keep it up !
Encouraging to see 2 directors between them bought 1.5m shares recently. Short term exit unlikely. Have been a shareholder for 5 years and now well in the money...tempting to take the money and run.
It has been a long time indeed but as the CEO said, most other proteomic companies are still not commercialised so we are and making a profit. Something to build on. When you say multi bagger, I am hoping for 20p but will re-evaluate once we get there. We traded at between 20-40p for a long time before dropping down to the lowest levels on the last CEO's reign. Some more PR and we could edge back up there
This could be a major multi-bagger. After years of disappointment it seems like they have established something which can be built on. The video seems realistic and measured. The other board seems full of bitter people who cannot move on at look forwards instead of going over old ground.
Just watched the presentation and was very interesting
https://www.youtube.com/watch?v=Vgf5hFwdods
....on not much trading. Someone sniffing about ?